Wide Ranks

HRMY

Harmony Biosciences Holdings, I

35.75

Top Statistics
Market Cap 2 B Forward PE 8.08 Revenue Growth 16.10 %
Current Ratio 3.24 Trailing PE 16.94 Earnings Growth 25.40 %
Profit Margins 17.98 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 9.09 Enterprise / Revenue 2.66 Price To Sales Trailing12 Months 2.99
Profitability
Profit Margins 17.98 % Operating Margins 33.17 %
Balance Sheet
Total Cash 410 M Total Cash Per Share 7.20 Total Debt 185 M
Total Debt To Equity 31.04 Current Ratio 3.24 Book Value Per Share 10.46
All Measures
Short Ratio 515.00 % Message Board Id finmb_679038073 Shares Short Prior Month 7 M
Return On Equity 0.2275 City Plymouth Meeting Uuid 13b9f8e2-d6d9-3fe8-a427-d46e3c835902
Previous Close 34.83 First Trade Date Epoch Utc 1 B Book Value 10.46
Beta 0.7700 Total Debt 185 M Volume 381199
Price To Book 3.42 Fifty Two Week Low 28.14 Total Cash Per Share 7.20
Total Revenue 681 M Shares Short Previous Month Date 1 B Target Median Price 52.00
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins 33.17 %
Target Mean Price 47.11 Net Income To Common 122 M Short Percent Of Float 0.4485
Implied Shares Outstanding 57 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 435790 Average Volume10days 435790 Total Cash 410 M
Next Fiscal Year End 1 B Revenue Per Share 11.92 Held Percent Insiders 0.1162
Ebitda Margins 29.27 % Trailing PE 16.94 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 34.83 Target Low Price 28.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 35.31 Open 34.87
Free Cashflow 168 M State PA Dividend Yield 0.00 %
Return On Assets 0.1285 Time Zone Short Name EST Trailing Eps 2.11
Day Low 34.81 Address1 630 West Germantown Pike Shares Outstanding 57 M
Price Hint 2 Target High Price 59.00 Website https://www.harmonybiosciences.com
52 Week Change 0.2302 Average Volume 735567 Earnings Quarterly Growth 19.80 %
Forward Eps 3.26 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 305.00 % Is_sp_500 False Regular Market Day High 35.96
Profit Margins 17.98 % Debt To Equity 31.04 Fifty Two Week High 41.61
Day High 35.96 Shares Short 5 M Regular Market Open 34.87
Industry Key biotechnology Earnings Growth 25.40 % Enterprise To Revenue 2.66
Revenue Growth 16.10 % Shares Percent Shares Out 0.1017 Operating Cashflow 220 M
Currency USD Time Zone Full Name America/New_York Market Cap 2 B
Is_nasdaq_100 False Zip 19462 Quote Type EQUITY
Industry Biotechnology Long Name Harmony Biosciences Holdings, Inc. Regular Market Day Low 34.81
Held Percent Institutions 0.9284 Current Price 35.75 Address2 Suite 215
Enterprise To Ebitda 9.09 Financial Currency USD Current Ratio 3.24
Gross Margins 78.65 % Industry Disp Biotechnology Number Of Analyst Opinions 9
Country United States Float Shares 44 M Two Hundred Day Average 32.99
Enterprise Value 1 B Price To Sales Trailing12 Months 2.99 Forward PE 8.08
Regular Market Volume 381199 Ebitda 199 M Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.

The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons.

The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020.

Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.